Skip to main content

Table 1 Demographic and clinical characteristics of RA patients treated with CTLA4-Ig at study entry

From: Peripheral blood CD4posCD25posFoxP3pos cells and inflammatory cytokines as biomarkers of response in rheumatoid arthritis patients treated with CTLA4-Ig

  Whole RA cohort
(n = 34)
RA cohort 1
(n = 15)
RA cohort 2
(n = 19)
p*
Age, years 56.2 ± 14.8 56.5 ± 15.6 55.8 ± 14.5 0.55
Sex, n, female (%) 28 (82.4) 14 (93.3) 14 (73.7) 0.14
Disease duration, years 4.3 ± 3.6 1.1 ± 0.9 6.8 ± 2.9 0.001
BMI, Kg/m2 25.9 ± 6.7 27.4 ± 8.7 24.7 ± 4.3 0.13
Smoking habit, n (%) 12 (35.5) 4 (26.7) 8 (42.1) 0.35
Anti-CCPpos, n (%) 28 (82.4) 12 (80.0) 16 (84.2) 0.79
RF-IgMpos, n (%) 20 (58.8) 6 (40.0) 14 (73.7) 0.05
RF-IgApos, n (%) 16 (47.1) 3 (20.0) 13 (68.4) 0.01
ESR, mm/1^hour 42.3 ± 23.7 38.7 ± 28.0 45.2 ± 19.3 0.27
CRP, mg/L 16.0 ± 15.6 14.2 ± 14.2 17.5 ± 13.3 0.44
DAS 3.9 ± 0.9 4.0 ± 0.1 3.9 ± 0.9 0.30
CDAI 30.0 ± 10.2 33.9 ± 10.2 27.5 ± 9.7 1.00
SDAI 31.3 ± 10.7 35.2 ± 10.6 28.8 ± 10.3 0.82
HAQ 1.2 ± 0.7 1.3 ± 0.8 1.2 ± 0.7 0.51
Erosive disease, n (%) 19 (55.9) 5 (33.3) 14 (73.7) 0.02
csDMARDs (ongoing), n (%) 34 (100.0) 15 (100.0) 19 (100.0) -
  1. Values are mean ± standard deviation unless otherwise indicated. RA rheumatoid arthritis, BMI body mass index, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS Disease Activity Score, ACPA anti-citrullinated peptide antibodies, RF rheumatoid factor, CDAI Clinical Disease Activity Index, SDAI Simplified Disease Activity Index, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, HAQ Health Assessment Questionnaire. *Mann–Whitney U test or chi-square test as appropriate between RA cohort 1 and RA cohort 2